📚 Stock Market Glossary

PROTAC (Proteolysis Targeting Chimera) is a transformative drug discovery platform that degrades and completely eliminates pathogenic proteins rather than merely blocking their active sites.

A PROTAC molecule consists of two functional heads connected by a chemical linker: one head binds selectively to the disease-causing target protein, while the other recruits an intracellular E3 ubiquitin ligase.

• From Inhibition to Complete Destruction: Traditional small molecules merely occupy the binding pocket of an enzyme. PROTAC flags the rogue protein with ubiquitin chains, prompting the cell's 26S proteasome garbage disposal to completely shred it.
• Conquering 'Undruggable' Targets: Over 80% of human disease-related proteins lack deep enzymatic pockets and were historically deemed undruggable. PROTAC needs only transient surface binding to trigger degradation.
• Sub-Stoichiometric Catalytic Activity: Once a target protein is degraded, the intact PROTAC molecule dissociates and repeats the degradation cycle for other target proteins, achieving exceptional potency at minimal dosages.

Big Pharma is aggressively licensing PROTAC assets to counter drug resistance in oncology and immunology. Watch clinical-stage biotechs demonstrating oral bioavailability, high target selectivity, and proprietary linker design libraries.